Surplus Solutions, an NMS Capital portfolio company focused on laboratory equipment and services, has acquired DCM BioServices Intelligence, a provider of lab automation solutions. The deal closed on July 6, 2026.
| Acquirer | Surplus Solutions (US) |
|---|---|
| Target | DCM BioServices Intelligence (US) |
| Value | Undisclosed |
| Type | Acquisition |
| Date Closed | 2026-07-06 |
| Date Announced | 2026-07-01 |
| Buy-side Advisors | XMS Capital |
| Sell-side Advisors | Not disclosed |
| Legal Buy-side | McDermott Will & Schulte |
| Legal Sell-side | Not disclosed |
The acquisition aims to expand Surplus Solutions' laboratory automation services, enhancing its technical capabilities and strategic position in the healthcare sector.
Deal Mechanics
Surplus Solutions purchased DCM BioServices Intelligence with the support of buy-side advisor XMS Capital. Legal counsel on the deal was provided by McDermott Will & Schulte on behalf of Surplus Solutions, while details about the sell-side advisors and legal representation remain undisclosed.
Strategic Rationale
The acquisition is part of a broader strategic initiative to bolster Surplus Solutions' service offerings in laboratory automation. With DCM BioServices Intelligence's expertise in this area, Surplus Solutions aims to provide clients with advanced lab solutions and improved operational efficiency.
Financial Context
Surplus Solutions was recently backed by growth equity firm NMS Capital, which has been actively investing in companies within the healthcare technology space. This acquisition is another step in the firm's broader strategy to build a leading platform for laboratory automation services and equipment.
Outlook
With the addition of DCM BioServices Intelligence, Surplus Solutions expects to enhance its market presence and accelerate growth through expanded service offerings. The company is optimistic about leveraging synergies between both organizations to deliver innovative solutions to healthcare customers.